|
 |
ThalomidThis page contains recent news articles, when available, and an overview of Thalomid but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.EntreMed has reported disappointing royalty revenues from sales of Thalomid, Celgene's drug to treat multiple myeloma, or cancer of the bone marrow. ... Business Gazette Multiple Myeloma Patients On Thalidomide At Risk For Infection Despite ... - Jan 1, 2010 Multiple myeloma patients on various thalidomide (Thalomid) combination regimens may develop infections despite preventative drug measures, according to a ... The Myeloma Beacon EntreMed Inc reports lower than expected royalty revenue from Thalomid sales in Q3 - Dec 14, 2009 EntreMed said that it plans to explore the sale of its rights to future royalties from sales of Thalomid and has started making additional expense ... Trading Markets (press release) Addition Of Thalidomide To Induction Therapy Increases Response Rates In ... - Dec 29, 2009 Preliminary results from a clinical trial designed to assess the effect of adding thalidomide (Thalomid) to induction therapy prior to autologous stem cell ... The Myeloma Beacon Velcade-Thalidomide-Dexamethasone Treatment Is Promising For Newly Diagnosed ... - Dec 30, 2009 ...thalidomide (Thalomid), and dexamethasone (Decadron), abbreviated as VTD, with a drug regimen of thalidomide and dexamethasone, abbreviated as TD, ... The Myeloma Beacon Unusual 11 Mid-Day Movers 12/14: LUNA, CAMD, SPDE, KRG Higher; CPF, OSK, ENMD ... - Dec 14, 2009 EntreMed (Nasdaq: ENMD) 10.9% LOWER; announced the receipt of $1.7 million in royalty revenue from sales of Thalomid during the third quarter compared to ... StreetInsider.com (subscription) EntreMed Reports Receipt of Third Quarter Royalty Payment - Dec 11, 2009 EntreMed also plans to explore the sale of its rights to future royalties from sales of Thalomid® and has instituted additional expense reductions in ... CNNMoney.com (press release) * Celgene's cancer drug Revlimid meets goal of CALGB trial - Dec 18, 2009 Revlimid is a derivative of thalidomide, sold by Celgene as Thalomid. (Reporting by Toni Clarke; editing by Dave Zimmerman and Andre Grenon) Reuters Perifosine Combination Therapy Is Promising For Relapsed And Refractory ... - Dec 17, 2009 ...treated with Velcade, and many had also been treated with dexamethasone, Revlimid (lenalidomide), thalidomide (Thalomid) or stem cell transplants. ... The Myeloma Beacon Novel Therapeutic Agents May Improve Kidney Impairment In Newly Diagnosed ... - Dec 26, 2009 Patients in group B received treatment with thalidomide (Thalomid) or Revlimid (lenalidomide) with high-dose dexamethasone and/or cyclophosphamide or ... The Myeloma Beacon Netlist, EntreMed: Midday Volume Plays - Dec 14, 2009 ...to 88 cents after the company said late Friday it had received $1.7 million in royalty revenue from sales of drug Thalomid during the third quarter, ... TheStreet.com Celgene Corporation (NASDAQ:CELG) to Present at Deutsche - Dec 10, 2009 The Company's commercial stage products include REVLIMID, THALOMID (inclusive of Thalidomide Pharmion), VIDAZA, ALKERAN and FOCALIN. On March 7, 2008, ... TransWorldNews (press release) Deals of the Week: Holiday Shopping - Dec 11, 2009 ...it would not need to add to its marketing and sales infrastructure since it already sells hematological cancer drugs Revlimid, Thalomid and Vidaza. ... The IN VIVO Blog (blog) The International Myeloma Foundation Says Important Studies May Offer New ... - Dec 10, 2009 This includes three-drug combinations such as VELCADE-REVLIMID-dexamethasone, VELCADE-cyclophosphamide-dexamethasone, VELCADE-THALOMID-dexamethasone, ... Medical News Today (press release) Celgene Scores with Multiple Myeloma Treatment Revlimid - Dec 21, 2009 However, sales of Celgene's Thalomid have been declining. We feel this decline will continue since more safe and effective drugs are available for multiple ... Seeking Alpha (blog) Celgene Position auflösen - Dec 14, 2009 1998 habe Celgene die Erlaubnis gewonnen, den von Grünenthal vor 50 Jahren entwickelten Wirkstoff Thalomid zu verwenden. Grünenthal habe vor 50 Jahren ... boerse.de (Pressemitteilung) Addition of Thalomid® to Autologous Stem Cell Transplantation May Improve ... - Oct 23, 2009 Thalomid® (thalidomide) is an active agent for the treatment of myeloma, and induction regimens that incorporate Thalomid have higher response rates than ... Cancer Consultants Celgene 3Q profit surges on cancer drug sales - Oct 22, 2009 The company also reported $110 million in Thalomid sales. Shares of Celgene rose $2.24, or 4.1 percent, to $58.82 in morning trading. ... The Associated Press Celgene (CELG): Bet on biotech for 'offense and defense' - Oct 27, 2009 They have a number of products at the commercial stage including REVLIMID, THALOMID and VIDAZA. "Celgene is also researching stem cells derived from the ... BloggingStocks (blog) Retreatment With Velcade As A Treatment Option For Relapsed Myeloma Patients - Oct 26, 2009 Velcade was administered as both a single-agent and in combination with dexamethasone (Decadron), thalidomide (Thalomid), and doxorubicin (Adriamycin). ... The Myeloma Beacon Thalidomide Improves Outcome Of Double Stem Cell Transplants In Younger ... - Oct 28, 2009 A study recently published in the Journal of Clinical Oncology suggests that thalidomide (Thalomid), used in conjunction with double autologous stem cell ... The Myeloma Beacon Celgene Reports Record Third Quarter 2009 Operating and Financial Results - Oct 22, 2009 THALOMID® net sales (inclusive of Thalidomide Pharmion and Thalidomide Celgene) were $110.0 million. VIDAZA net sales were $103.1 million, an increase of 62 ... Reuters New Recommendations Issued On Stem Cell Collection And Treatment With Revlimid ... - Oct 22, 2009 ...had some financial ties to pharmaceutical companies, including Millennium, manufacturer of Velcade, and Celgene, manufacturer of Revlimid and Thalomid. ... The Myeloma Beacon Generics firms call Big Pharma anticompetitive - Nov 12, 2009 Dr. Reddy's says it can't get ahold of Celgene's multiple myeloma drugs Revlimid and Thalomid; that company also cited safety issues for the refusal. ... FiercePharma The Life-and-Death Situation That Isn't - Nov 12, 2009 ...is there to prevent use of the drug by patients who shouldn't be taking Thalomid -- people like pregnant women -- because the drug causes birth defects. ... Motley Fool Thalidomide in combination with chemotherapy did not improve advanced NSCLC ... - Oct 26, 2009 In a phase-3 trial, researchers randomly assigned 350 patients to placebo and 372 patients to thalidomide (Thalomid, Celgene) capsules 100 mg to 200 mg per ... HemOncToday NeurogesX Expands Commercial Operations Leadership Team - Nov 5, 2009 In her role at Celgene, she was involved with the launch of Thalomid® and related risk management program STEPS®. From 1988 to 1997 Ms. Cavers worked at ... Reuters Multiple Myeloma Study Finds “Complete Responseâ€? Is Generally Correlated With ... - Oct 20, 2009 ...patients increased rapidly with newer treatment therapies that include thalidomide (Thalomid), Velcade (bortezomib), and Revlimid (lenalidomide). ... The Myeloma Beacon More Than 200 Abstracts Evaluating Celgene Products across a Range of ... - Nov 11, 2009 VIDAZA ® , THALOMID ® , pomalidomide, ACE-011 and Amrubicin at the 51st Annual American Society of Hematology Meeting and Exposition from December 5-8, ... WELT ONLINE FDA's Risk Mitigation Rules Are Opening a Pandora's Box - Nov 6, 2009 Celgene is again an example: Its STEPS program for ensuring safe access to Thalomid, its version of the notoriously teratogenic drug thalidomide, ... Therapeutics Daily (press release) (registration) Celgene Corporation - Pharmaceuticals & Healthcare - Deals and Alliances ... - Nov 9, 2009 The company has three marketed products REVLIMID, THALOMID and VIDAZA. It is headquartered in Summit, New Jersey, United States Pharmaceuticals & Healthcare ... PR-Inside.com (Pressemitteilung) Treatment Trends For Multiple Myeloma – Part 1: Autologous Stem Cell Transplants - Nov 3, 2009 The other trial, presented to the American Society of Hematology, found a Velcade, thalidomide (Thalomid), and dexamethasone induction regimen caused a very ... The Myeloma Beacon Celgene Corp. Reports Operating Results (10-Q) - Oct 30, 2009 THALOMID® net sales decreased by $22.3 million to $110.0 million for the three-month period ended September 30, 2009 compared to the three-month period ... GuruFocus.com Celgene Reports Record Third Quarter 2009 Operating and Financial Results - Oct 22, 2009 THALOMID net sales for the first nine months of 2009 were $329.2 million. Vidaza net sales for the first nine months of 2009 reached $270.5 million, ... Business Wire (press release) About this author: - Oct 21, 2009 Celgene (CELG) is expected to report Q3 earnings Thursday, October 22 before market open, with a conference call scheduled for 9:00 am ET. ... Seeking Alpha (blog) Celgene 盈馀高於预期，股价上扬4.6% - Oct 22, 2009 ...å…¬å?¸å…¬å¸ƒç¬¬ä¸‰å£Revlimid销售é¢?为4.29忆美元，市场预期4.29忆；Vidaza销售é¢?1.03忆美元，市场预期1.08忆美元；Thalomid销售é¢?1.1忆美元，市场预期1.02忆美元。 ... 凤凰网 Celgene erste Position eröffnen - Heibel-Ticker - Nov 2, 2009 USD Umsatz habe das Medikament Thalomid beigetragen - ein Medikament, das auf dem Wirkstoff beruhe, der in Deutschland um 1960 den Contergan-Skandal ... Stock World Beursadvies ABN AMRO over CELGENE CORPORATION - Oct 23, 2009 De analisten van ABN AMRO stellen dat vooral de verkoop van Revlimid en Thalomid voor Celgene goed verliepen. Deze medicijnen helpen tegen bloedkanker. ... Analist.be Celgene's Thalomid Gets Its Due - May 25, 2006 By Althea Chang. Regulators have cleared Celgene's (CELG - commentary - Cramer's Take) leprosy drug Thalomid as a treatment option for newly diagnosed cases ... TheStreet.com - TheStreet.com (subscription) Thalomid Fuels Celgene's Rise - Jan 9, 2006 A new study shows that Thalomid, from Celgene, can triple the amount of time patients with the blood cancer multiple myeloma can live without their disease ... Forbes Celgene sees Revlimid sales surpassing Thalomid - Feb 23, 2006 BOSTON (Reuters) - The chief operating officer of Celgene Corp. (CELG.O: Quote, Profile, Research, Stock Buzz) said on Thursday he expects sales of the ... Reuters Big Growth Seen at Celgene - Jul 27, 2005 Thalomid is Celgene's branded version of the drug thalidomide, ... Celgene could face generic competition for Thalomid in the not-too-distant future. ... TheStreet.com - TheStreet.com (subscription) Barr Files for Generic Thalomid; Celgene Will Resist - Dec 13, 2006 By Susan Decker and Angela Zimm. Dec. 13 (Bloomberg) -- Barr Pharmaceuticals Inc., the second-largest US generic-drug maker, filed with regulators to sell a ... Bloomberg Celgene/Pharmion Deal Paces Biotechs - Nov 19, 2007 Celgene's top seller is Thalomid, a brand name for the drug thalidomide, which was linked ... Pharmion markets Thalomid outside the US (See “Drug Rehabâ€?). ... Forbes Thalomid Has Long-Term Suitability Doubts - Dec 13, 2005 By Althea Chang 12/13/05 - 11:30 AM EST. A study of Celgene's (CELG Quote) drug Thalomid showed that despite its effectiveness in treating the blood cancer ... TheStreet.com - TheStreet.com (subscription) Barr says Celgene files suit for Thalomid capsules - Jan 23, 2007 Jan 23 (Reuters) - Barr Pharmaceuticals Inc. BRL.N confirmed that Celgene Corp. (CELG.O) has filed suit in a federal court to prevent Barr from selling its ... Reuters Petition Seeks Warning on Anticancer Medication - May 4, 2005 In the petition, Mr. Blumenthal also said Celgene, the maker of Thalomid, ... Thalomid is an unusual medicine. Known generically as thalidomide, ... New York Times … has two multiple myeloma drugs: Revlimid, Thalomid - Jun. 30, 2006 - Jun 30, 2006 By Aaron Smith, CNNMoney.com staff writer. NEW YORK (CNNMoney.com) -- The FDA approved a drug combo from Celgene that slows the spread of blood cancer, ... CNNMoney.com Celgene sees 2007 EPS below Street view - Jan 8, 2007 Celgene said sales of Revlimid reached $315 million to $320 million for 2006, while Thalomid sales reached $425 million to $430 million. ... Reuters FDA Wants More Data From Celgene - Nov 15, 2005 Though Thalomid is FDA-approved specifically for treating leprosy, ... Celgene's application to market Thalomid for multiple myeloma was based on the ... TheStreet.com - TheStreet.com (subscription) Celgene profit jumps; boosts 2008 outlook - Oct 23, 2008 Sales of Revlimid, a successor to Celgene's cancer drug Thalomid, rose 72 percent to $343 million -- just below the consensus estimate of $347 million. ... Reuters Study reveals promise for two Celgene drugs - Jun. 5, 2006 - Jun 5, 2006 ..."This clearly demonstrates that both Thalomid and Revlimid should be, ... Thalidomide, the base compound for Thalomid, has a notorious history as a ... CNNMoney.com Barr wants to market a version of Thalomid.(RX RETAIL PHARMACY: … - Jan 22, 2007 WOODCLIFF LAKE, NJ -- Barr Laboratories Inc. has filed an abbreviated new drug application with the Food and Drug Administration to manufacture and market a ... Free with registration - Chain Drug Review - AccessMyLibrary.com FDA Advisory Panel Backs an Anemia Drug - Sep 15, 2005 Although it is approved to treat a complication of leprosy, Thalomid is mainly used off-label for multiple myeloma, a bone marrow cancer. ... New York Times Celgene Might Be Trouble for Millennium - Apr 26, 2006 ..."Although Thalomid could be formally approved in front-line [multiple ... Thalomid currently dominates the multiple myeloma market despite only being ... TheStreet.com - TheStreet.com (subscription) Celgene 4th-qtr profit rises on cancer drug sales - Feb 1, 2007 Revenue rose 84 percent to $275 million, driven by sales of the company's blood cancer drugs Revlimid and Thalomid. The company said it expects total ... Reuters FDA Delays Decision On Celgene Drug - Oct 3, 2005 Revlimid is a newer version of thalidomide, which Celgene sells under the brand name Thalomid. Although Thalomid is a mainstay in the treatment of multiple ... Forbes Celgene Halts Drug Trial Over Blood Clot Fears - Sep 28, 2005 Celgene already sells another form of thalidomide under the name Thalomid, which is used to treat myeloma and leprosy. The company has developed a protocol ... RedOrbit Thalomid With Chemotherapy Helps Older Myeloma Patients - Mar 10, 2006 By Judith Groch,. TURIN, Italy, March 10 - A second study in less than a week has found that Thalomid (thalidomide) has a place in first-line therapy for ... MedPage Today ARGUS Maintains a Hold Rating on Celgene (CELG), Sees Volatile … - Aug 28, 2008 The company's other key products are Thalomid, to treat multiple myeloma and leprosy, and Vidaza, another MDS agent, gained through the acquisition of ... StreetInsider.com - StreetInsider.com (subscription) Thalomid gets FDA approval to treat multiple myeloma - May 29, 2006 Thalomid (thalidomide) has been given a new lease of life following the United States Food and Drug Administration (FDA) approval for the drug to be used in ... News-Medical.net Thalidomide: Research advances in cancer and other conditions - Dec 20, 2008 Thalomid (prescribing information). Summit, NJ: Celgene Corp.; ... Patient information sheet thalidomide (marketed as Thalomid). ... MayoClinic.com Barr Confirms Generic Thalomid(R) Capsule, 50 mg and 100 mg … - Dec 26, 2006 WOODCLIFF LAKE, NJ, Dec. 26 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. , today confirmed that it is ... Free with registration - PR Newswire - AccessMyLibrary.com Prioritizing Millennium - Jan 31, 2008 Currently, only Celgene's (Nasdaq: CELG) rival compound Thalomid is approved as a front-line drug for multiple myeloma patients, but another Celgene drug, ... fool.com Press Release: Barr Confirms Generic Thalomid(R) Suit Filed. - PR … - Jan 23, 2007 Barr Confirms Generic Thalomid(R) Suit Filed. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Celgene cancer drug gets boost from data - Dec 13, 2006 Revlimid is a successor drug to Celgene's Thalomid, the leading treatment for ... Thalomid plus dexamethasone is typically the first choice of treatment for ... Pay-Per-View - Star-Ledger - Factiva, from Dow Jones BARR CONFIRMS GENERIC THALOMID APPLICATION - Jan 2, 2007 Barr Laboratories, a subsidiary of Barr Pharmaceuticals, Dec. 26 confirmed that it is seeking approval from the FDA to manufacture and market a generic ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Projects: Customer Service Celgene Voice Recognition Helps Manage … - Dec 6, 2005 STEPS also tracks the whereabouts of Thalomid packages by attaching ... Thalomid can be an effective cancer drug for the same reason that it harms ... Baseline Celgene Reports Record Growth as Sales of Key Cancer Drug More Than … - Jan 15, 2008 The company also reported good sales results for Thalomid (thalidomide), Alkeran (melphalan), Focalin XR (dexmethylphenidate HCl) and the Ritalin ... FDA news - FDA news (subscription) Celgene (CELG) Said ANDA Filing for Generic THALOMID Filed with FDA - Dec 26, 2006 Celgene Corporation (Nasdaq: CELG) has been notified of an Abbreviated New Drug Application filed with the FDA, with a Paragraph IV certification, ... StreetInsider.com - StreetInsider.com (subscription) Barr wants to market a version of Thalomid.(RX RETAIL PHARMACY: … - Jan 22, 2007 Barr wants to market a version of Thalomid.(RX RETAIL PHARMACY: Generic Drugs)(Barr Laboratories Inc.)(Brief article) ... find Chain Drug Review articles. Pay-Per-View - Chain Drug Review - HighBeam Research What is New in Multiple Myeloma? - Update From ASH 2005 - Dec 10, 2005 Revlimid is a Thalomid® (thalidomide) analogue, which belongs to the group of ... Revlimid has a different side-effect profile compared to Thalomid. ... Cancer Consultants Celgene: Thalomid slows progression of multiple myeloma - Jan 10, 2006 Celegene has announced that it will halt a phase III trial of Thalomid plus dexamethasone in multiple myeloma after an analysis showed the combination to ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones Analysis: Street likes Celgene's Revlimid. - Jun 13, 2007 ..."It will completely outshine Thalomid and Velcade," he said. ... He also sees the drug stealing market share from Thalomid and Velcade. ... Free with registration - UPI Health Business - AccessMyLibrary.com Celgene's Thalomid plus topotecan superior to topotecan alone. - Nov 14, 2005 US drugmaker Celgene Corp says that a Phase II randomized, multicenter clinical study of Thalomid (thalidomide) in treatment-naive recurrent epithelial ... Free with registration - Pharma Marketletter - AccessMyLibrary.com An Update of Treatments for Multiple Myeloma: Results from the 2006 … - Dec 9, 2006 The MAG group compared Thalomid® (thalidomide) + Dex induction to VAD prior ... 2] The Thalomid + Dex group achieved a VGPR or better of 25% compared to 7% ... Cancer Consultants Millennium: Positive Velcade Phase III Results In New MM - Sep 19, 2007 ...s Revlimid (lenalidomide, a derivative of Thalomid, the company's brand name ... "However, given our expectation that Thalomid, and increasingly Revlimid, ... BioWorld Online - BioWorld Online Finance; Thalomid maker reports strong revenue growth and profits - Feb 22, 2005 2005 FEB 22 - (NewsRx.com & NewsRx.net) -- Celgene Corp. (CELG) announced adjusted diluted earnings per share of $0.10 for the quarter ended December 31, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |